NASDAQ : ONCO
Onconetix, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.586 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.31M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.22M |
| Enterprise Value | -3.54M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.95M |
| Shares Outstanding | 3.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +3,468.28% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 7.39% |
| Float | 3.95M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.43 |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.21 |
| Quick Ratio | 2.04 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.72 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -105.23% |
| Return on Assets (ROA) | -27.03% |
| Return on Invested Capital (ROIC) | -33.93% |
| Return on Capital Employed (ROCE) | -57.02% |
| Weighted Average Cost of Capital (WACC) | 27.37% |
| Revenue Per Employee | $322,912 |
| Profits Per Employee | -$5.10M |
| Employee Count | 2 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.70 |
Taxes
| Measure | Value |
|---|
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.61 |
| 52-Week Price Change | -99.69% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 13.89 |
| Relative Strength Index (RSI) | 48.47 |
| Average Volume (20 Days) | 5,548,018 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 389,871 |
| Short Previous Month | 489,621 |
| Short % of Shares Out | 9.87% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 645,824 |
| Gross Profit | 519,226 |
| Operating Income | -7.69M |
| Pretax Income | -10.20M |
| Net Income | -10.20M |
| EBITDA | -7.67M |
| EBIT | -7.69M |
| Loss Per Share | -$17.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.94M |
| Total Debt | 187,128 |
| Net Cash | 5.76M |
| Net Cash Per Share | $1.46 |
| Equity (Book Value) | 13.47M |
| Book Value Per Share | 3.55 |
| Working Capital | 3.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 14,753 |
| Net Borrowing | -4.56M |
| Free Cash Flow | -10.31M |
| FCF Per Share | -$2.61 |
Margins
| Measure | Value |
|---|
| Gross Margin | 80.40% |
| Operating Margin | -1,190.29% |
| Pretax Margin | -1,578.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3,058.08% |
| FCF Yield | -465.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 53.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -12.46 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |